Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 225

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 6
Chunk 225
---
, 2024       November 13, 2024    
  Vesting Period                                                    3 years                   3 years                   3 years                 3 years              
  Holding period                                                    None                      None                      None                    None                 
  Performance Conditions                                            No                        No                        No                      No                   
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Number of AGA granted                                             25,000                    25,000                    370,560                 200,000              
  Number of vested AGA as of December 31, 2024                      0                         0                         0                       0                    
  Number of lapsed AGA as of December 31, 2024                      0                         0                         1,800                   0                    
  Number of AGA under a vesting period as of December 31, 2024      25,000                    25,000                    368,760                 200,000              

The following authorization will be submitted for approval to the general meeting of the shareholders to be held on May 22, 2025: (i) up to 1,275,000 free shares with performance conditions to the benefit of executive officers, employed members of the Leadership Team, employed senior executives and/or corporate officers, (ii) up to 1,500,000 free shares with performance conditions to the benefit of employees, (iii) up to 100,000 free shares to the benefit of new executive officers without performance conditions, (iv) up to 150,000 free shares to the benefit of executive officers, employed members of the Executive Committee, employed senior executives and/or corporate officers, (v) up to 500,000 free shares to the benefit of employees, (vi) up to 300,000 free shares to the benefit of employees and Leadership

Team and Executive Board (excluding the Chairman) members as part of the employee saving plan and (vii) up to 60,000 warrants to the benefit of independent Supervisory Board members to be issued at the fair market value.

Free Preferred Shares (AGAP)

Free preferred shares (AGAP) are another employee equity incentive instrument similar to the free shares or AGA, except that, after a one-year vesting period, the beneficiaries receive a preferred shares (shares B) which will become convertible into ordinary shares following a lock-up period of two additional years, if the performance conditions (and a presence condition) are